LMR Partners’s Viridian Therapeutics VRDN Stock Holding History

LMR Partners’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$184K	Buy	10,000 +8,841	+763%	+$142K	﹤0.01%	1328
2026 Q1	$22.7K	Buy	+1,159	New	+$34.4K	﹤0.01%	1344
2024 Q1	–	Sell	-10,000	Closed	-$218K	–	1324
2023 Q4	$218K	Hold	10,000	–	–	﹤0.01%	726
2023 Q3	$153K	Hold	10,000	–	–	﹤0.01%	653
2023 Q2	$238K	Sell	10,000 -10,000	-50%	-$256K	﹤0.01%	572
2023 Q1	$509K	Sell	20,000 -30,000	-60%	-$962K	0.01%	730
2022 Q4	$1.46M	Buy	50,000 +9,213	+23%	+$212K	0.03%	620
2022 Q3	$837K	Sell	40,787 -39,610	-49%	-$712K	0.02%	780
2022 Q2	$930K	Buy	80,397 +27,623	+52%	+$371K	0.02%	789
2022 Q1	$976K	Buy	52,774 +11,374	+27%	+$219K	0.01%	839
2021 Q4	$818K	Buy	41,400 +7,892	+24%	+$147K	0.01%	788
2021 Q3	$551K	Buy	+33,508	New	+$491K	0.01%	763
2019 Q4	–	Sell	-989	Closed	-$11K	–	560
2019 Q3	$11K	Hold	989	–	–	﹤0.01%	411
2019 Q2	$30K	Buy	+989	New	+$39.7K	﹤0.01%	390

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LMR Partners's VRDN Position: Q2 2026 in Review

LMR Partners increased its Viridian Therapeutics (VRDN) stake by 763% in Q2 2026, buying an estimated $142K and bringing the position to 10,000 shares worth $184K. The position accounts for ﹤0.01% of the portfolio, ranked #1328.

LMR Partners first reported a position in VRDN in Q2 2019 and has held it in 14 quarters since. The position peaked at $1.46M in Q4 2022. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

LMR Partners held 10,000 shares of Viridian Therapeutics worth $184K as of Q2 2026.
LMR Partners bought 8,841 Viridian Therapeutics shares in Q2 2026, an estimated $142K.
Viridian Therapeutics made up ﹤0.01% of LMR Partners's portfolio in Q2 2026, its #1328 holding.
LMR Partners first reported a position in Viridian Therapeutics in Q2 2019 and has held it in 14 quarters since.
LMR Partners's Viridian Therapeutics position peaked at $1.46M in Q4 2022.
214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.